Overcoming breast cancer heterogeneity and resistance using a novel therapeutic approach targeting the metastasis suppressor NDRG1.

使用针对转移抑制因子 NDRG1 的新型治疗方法克服乳腺癌异质性和耐药性。

• 批准号: nhmrc : GNT1140447
• 负责人: Dr Zaklina Kovacevic
• 金额: $ 43.1万
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/overcoming-breast-cancer-suppressor-ndrg1/1348308
• 关键词: Overcoming; breast; cancer; heterogeneity; resistance

Breast cancer (BrCa) is the leading cause of cancer death in women and current treatments suffer from development of resistance, leading to metastatic progression. I will assess a novel treatment strategy for BrCa, targeting a gene that is able to inhibit multiple key drivers of BrCa, using a novel potent and selective anti-cancer agent. This approach has the potential to overcome resistance to current therapies and alleviate the onset of metastasis, to improve prognosis for BrCa patients.

乳腺癌 (BrCa) 是女性癌症死亡的主要原因，目前的治疗方法会产生耐药性，导致转移进展。我将评估一种针对 BrCa 的新型治疗策略，该策略针对能够抑制 BrCa 多个关键驱动因素的基因，使用一种新型有效且选择性的抗癌药物。这种方法有可能克服对当前疗法的耐药性并减轻转移的发生，从而改善 BrCa 患者的预后。